Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sarah Esposito

Physician Assistant Spotswood, NJ Physician Assistant

NPI 1760775589 CMS profile 11131815

296 Summerhill Rd Ste 100, Spotswood, NJ 08884

Open in the dashboard

General payments

$7,237

446 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Esposito of Spotswood, NJ is reported in the CMS Open Payments database as having received $7,237 across 446 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,101 105
2024 General $1,651 103
2023 General $1,400 87
2022 General $1,164 83
2021 General $921 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Esposito
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sarah Esposito were reported at $2,101. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sarah Esposito Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $921 $132 $37–$438 $132
2022 $1,164 $155 $48–$522 $149
2023 $1,400 $167 $52–$557 $160
2024 $1,651 $178 $55–$600 $164
2025 $2,101 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $785 35 payments
  2. Dermavant Sciences, Inc. $653 47 payments
  3. Mayne Pharma Inc. $575 49 payments
  4. AbbVie, Inc. $554 36 payments
  5. Incyte Corporation $407 25 payments
  6. Sun Pharmaceutical Industries Inc. $405 23 payments
  7. LEO Pharma Inc. $323 23 payments
  8. Novartis Pharmaceuticals Corporation $290 14 payments
  9. Amgen Inc. $289 18 payments
  10. Pfizer Inc. $265 10 payments
  11. Other $2,690 166 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,717 438 payments
  2. Education $520 8 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $775 34 payments
  2. VTAMA $697 51 payments
  3. OPZELURA $407 25 payments
  4. DUPIXENT $297 15 payments
  5. Otezla $289 18 payments
  6. CIBINQO $265 10 payments
  7. SOTYKTU $258 18 payments
  8. ADBRY $247 18 payments
  9. LITFULO $240 8 payments
  10. SKYRIZI $216 14 payments
  11. Other $3,875 250 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

835

Median for Physician Assistant: 241

Drug cost

$185,716

Median for Physician Assistant: $4,110

Branded share of claims

11.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 16 $106,905
Otezla Apremilast Brand 13 $61,267
Ketoconazole Generic 191 $2,980
Tacrolimus Generic 35 $2,690
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 44 $1,802
Clobetasol Propionate Generic 33 $1,800
Ciclopirox Generic 18 $1,207
Tretinoin Generic 11 $1,135
Mupirocin Generic 175 $988
Triamcinolone Acetonide Generic 76 $988

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$167,858

Of which drugs: $9,035

Medicare patients

453

Average age 73

Services billed

10,478

239 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 42%
Diabetes 30%
Ischemic heart disease 28%
Cancer 17%
Chronic kidney disease 16%
Atrial fibrillation 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 29 6,800 $9,019

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $246
$246 — —
VTAMA
  • Dermavant Sciences, Inc. $222
$222 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $153
$153 — —
OPZELURA
  • Incyte Corporation $106
$106 — —
Bimzelx
  • UCB, Inc. $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

446 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record